Surgery of Melanoma Metastases After Systemic Therapy
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma
patients with partial response or stable disease after a minimum 9 months of first-line PD-1
inhibition. Primary endpoint: Disease-free survival (DFS) at 12 months.